30 research outputs found
A Decade of Making Dreams into Reality: Lessons from the I Have A Dream Program
Ten years ago, Eugene Lang startled a graduating class of East Harlem sixth-graders by promising to pay for their college educations. He had been advised by their principal that most of the students would drop out before completing high school; Lang hoped the tuition promise would motivate them to stay in school. But Lang soon discovered he needed to provide more than money to make the distant prospect of college a reality for his students, whom he called Dreamers. To augment his promise, Lang rented a meeting space and hired Johnny Rivera, a young caseworker with a neighborhood social service organization, to coordinate support services for the Dreamers and their families. Over the next ten years, Lang and Rivera worked closely with the students, as mentors and motivators. Most importantly, they built caring, personal relationships with their Dreamers. The original inspiration of the scholarship promise, combined with a decade of guidance and support, produced striking results
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22:Nuclear hormone receptors
The Concise Guide to PHARMACOLOGY 2021/22 is the fifth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of nearly 1900 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes over 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, pointâinâtime record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/bph.15540. Nuclear hormone receptors are one of the six major pharmacological targets into which the Guide is divided, with the others being: G proteinâcoupled receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to midâ2021, and supersedes data presented in the 2019/20, 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NCâIUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate
Software for the frontiers of quantum chemistry:An overview of developments in the Q-Chem 5 package
This article summarizes technical advances contained in the fifth major release of the Q-Chem quantum chemistry program package, covering developments since 2015. A comprehensive library of exchangeâcorrelation functionals, along with a suite of correlated many-body methods, continues to be a hallmark of the Q-Chem software. The many-body methods include novel variants of both coupled-cluster and configuration-interaction approaches along with methods based on the algebraic diagrammatic construction and variational reduced density-matrix methods. Methods highlighted in Q-Chem 5 include a suite of tools for modeling core-level spectroscopy, methods for describing metastable resonances, methods for computing vibronic spectra, the nuclearâelectronic orbital method, and several different energy decomposition analysis techniques. High-performance capabilities including multithreaded parallelism and support for calculations on graphics processing units are described. Q-Chem boasts a community of well over 100 active academic developers, and the continuing evolution of the software is supported by an âopen teamwareâ model and an increasingly modular design
A Decade of Making Dreams into Reality: Lessons from the I Have A Dream Program
Ten years ago, Eugene Lang startled a graduating class of East Harlem sixth-graders by promising to pay for their college educations. He had been advised by their principal that most of the students would drop out before completing high school; Lang hoped the tuition promise would motivate them to stay in school. But Lang soon discovered he needed to provide more than money to make the distant prospect of college a reality for his students, whom he called Dreamers. To augment his promise, Lang rented a meeting space and hired Johnny Rivera, a young caseworker with a neighborhood social service organization, to coordinate support services for the Dreamers and their families. Over the next ten years, Lang and Rivera worked closely with the students, as mentors and motivators. Most importantly, they built caring, personal relationships with their Dreamers. The original inspiration of the scholarship promise, combined with a decade of guidance and support, produced striking results
Paraffin immunofluorescence in the renal pathology laboratory: more than a salvage technique
Spiritual Well-Being, Dissociation, and Alexithymia: Examining Direct and Moderating Effects
Discovery and characterization of a potent interleukin-6 binding peptide with neutralizing activity in vivo
Interleukin-6 (IL-6) is an important member of the cytokine superfamily, exerting pleiotropic actions on many physiological processes. Over-production of IL-6 is a hallmark of immune-mediated inflammatory diseases such as Castlemanâs Disease (CD) and rheumatoid arthritis (RA). Antagonism of the interleukin IL-6/IL-6 receptor (IL-6R)/gp130 signaling complex continues to show promise as a therapeutic target. Monoclonal antibodies (mAbs) directed against components of this complex have been approved as therapeutics for both CD and RA. To potentially provide an additional modality to antagonize IL-6 induced pathophysiology, a peptide-based antagonist approach was undertaken. Using a combination of molecular design, phage-display, and medicinal chemistry, disulfide-rich peptides (DRPs) directed against IL-6 were developed with low nanomolar potency in inhibiting IL-6-induced pSTAT3 in U937 monocytic cells. Targeted PEGylation of IL-6 binding peptides resulted in molecules that retained their potency against IL-6 and had a prolongation of their pharmacokinetic (PK) profiles in rodents and monkeys. One such peptide, PN-2921, contained a 40 kDa polyethylene glycol (PEG) moiety and inhibited IL-6-induced pSTAT3 in U937 cells with sub-nM potency and possessed 23, 36, and 59 h PK half-life values in mice, rats, and cynomolgus monkeys, respectively. Parenteral administration of PN-2921 to mice and cynomolgus monkeys potently inhibited IL-6-induced biomarker responses, with significant reductions in the acute inflammatory phase proteins, serum amyloid A (SAA) and C-reactive protein (CRP). This potent, PEGylated IL-6 binding peptide offers a new approach to antagonize IL-6-induced signaling and associated pathophysiology